Oruka Therapeutics (ORKA) Long-Term Investments (2016 - 2026)
Oruka Therapeutics' quarterly Long-Term Investments came in at $107.1 million in Q1 2026, up 347.22% year-on-year from $24.0 million in Q1 2025, and down 24.85% quarter-over-quarter from $142.5 million in Q4 2025.
Oruka Therapeutics has reported Long-Term Investments for 4 years, with the latest figure at $107.1 million in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Investments rose 347.22% year-over-year to $107.1 million; the trailing twelve-month figure through Mar 2026 stood at $107.1 million (up 347.22% YoY), and the FY2025 full-year result was $142.5 million, up 688.86% from the prior year.
- Long-Term Investments for Q1 2026 stood at $107.1 million, down from $142.5 million in the prior quarter.
- The five-year high for Long-Term Investments was $151.8 million in Q3 2025, with the low at $18.1 million in Q4 2024.
- Average Long-Term Investments over 3 years is $77.8 million, with a median of $65.5 million recorded in 2025.
- Year-over-year, Long-Term Investments jumped 688.86% in 2025 and surged 347.22% in 2026.
- Tracing ORKA's Long-Term Investments over 3 years: stood at $18.1 million in 2024, then jumped by 688.86% to $142.5 million in 2025, then retreated by 24.85% to $107.1 million in 2026.
- The last three Long-Term Investments figures came in at $107.1 million (Q1 2026), $142.5 million (Q4 2025), and $151.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | 107.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 107.12 Mn |
| Dec 31, 2025 | 142.54 Mn |
| Sep 30, 2025 | 151.76 Mn |
| Jun 30, 2025 | 23.05 Mn |
| Mar 31, 2025 | 23.95 Mn |
| Dec 31, 2024 | 18.07 Mn |
| Dec 31, 2016 | 2.35 Mn |
| Sep 30, 2016 | 3.97 Mn |
| Jun 30, 2016 | 5.01 Mn |
| Mar 31, 2016 | 5.31 Mn |